studies

breast cancer - HER2-positive, TKI anti HER1/EGFR and HER2/neu vs. non platinum-based chemotherapy, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsEGF100151, 2006 0.81 [0.65; 1.00] 0.81[0.65; 1.00]EGF100151, 200610%324NAnot evaluable objective responses (ORR)detailed resultsEGF100151, 2006 1.70 [0.96; 3.03] 1.70[0.96; 3.03]EGF100151, 200610%324NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsEGF100151, 2006 1.15 [0.59; 2.25] 1.15[0.59; 2.25]EGF100151, 200610%316NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-06-02 06:30 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 422,1304,421,1312,1326,1368,1373,1309,1302,1308

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons